Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting - Episode 5

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

April 11, 2024

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

EP. 2: Selecting Optimal 3L Colorectal Cancer Treatment

EP. 3: Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

EP. 4: General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

Now Viewing

EP. 5: Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

EP. 6: Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

EP. 7: Treatment Considerations With Regorafenib in Colorectal Cancer

EP. 8: Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

EP. 9: FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

EP. 10: Monitoring and AE Management Strategies with Fruquintinib in CRC

EP. 11: Toxicity Considerations and Treatment Decisions in CRC

EP. 12: Multidisciplinary Care for Patients with CRC

EP. 13: Unmet Needs and Future Perspectives in Colorectal Cancer